Stephen D. Collins

Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA.

Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL.

OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL.

NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL.

Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia.

Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL.

Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA.